跳至主要内容
临床试验/NCT07675434
NCT07675434尚未招募不适用

CESAR Study: Prospective Cohort of Consecutive Patients Undergoing Cardiologic Evaluation in a Specialized Ambulatory Referral Unit

Assistance Publique - Hôpitaux de Paris0 个研究点目标入组 25,000 人开始时间: 2026年8月1日最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
入组人数
25,000
主要终点
Proportion of patients with confirmed cardiovascular diagnosis among consecutive patients consulting for suspicion of acute or sub-acute cardiovascular disease at the ambulatory day-hospital unit.

研究概览

简要总结

Suspected acute or subacute cardiovascular diseases-including chest pain, dyspnea, and palpitations-are among the most common reasons for unscheduled emergency department visits and pre-hospital referrals. Despite this high clinical burden, the diagnostic yield is often limited, with a frequent mismatch between initial clinical suspicion and final diagnosis, contributing to substantial healthcare utilization and hospitalization rates. Current evidence is largely focused on specific conditions such as acute coronary syndromes, heart failure, arrhythmias, or pulmonary embolism, and rarely integrates the full spectrum of clinical, biological, and imaging data obtained during initial evaluation.

To address this gap, we will establish a prospective cohort of all consecutive patients referred to the ambulatory day-hospital cardiology unit at Lariboisière University Hospital. This unit acts as a specialized downstream referral structure within the emergency care pathway, receiving patients after triage by emergency physicians, pre-hospital regulation services (SAMU), mobile intensive care units (SMUR), or emergency departments. Although it does not capture all suspected cardiovascular emergencies, it represents a selected real-world population deemed to require specialized acute cardiology assessment.

The primary objective is to assess the frequency of cardiac conditions diagnosed in this cohort. Secondary objectives include characterization of patient profiles and diagnostic pathways; evaluation of the diagnostic and prognostic performance of clinical, biological, imaging, and multimodal parameters using final Heart Team diagnosis as reference; analysis of prior health history and healthcare utilization; and assessment of the medico-economic burden of suspected acute cardiovascular disease. The study will further support the development of a dedicated biobank and the validation of next-generation biomarkers, including AI-driven and voice-based markers, as well as decision-support algorithms for binary classification of cardiac involvement. Through integration of multimodal data and linkage with national health records, this approach aims to improve diagnostic accuracy, risk stratification, and understanding of the healthcare impact of acute cardiovascular presentations in a real-world setting.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • - The study will include all consecutive patients referred to ambulatory day-hospital unit for suspicion of acute or sub-acute cardiovascular disease at the Cardiology Department of Lariboisière University Hospital.

排除标准

  • Patient unable to provide informed consent
  • Patient not affiliated to French social security

结局指标

主要结局

Proportion of patients with confirmed cardiovascular diagnosis among consecutive patients consulting for suspicion of acute or sub-acute cardiovascular disease at the ambulatory day-hospital unit.

时间窗: From enrollement to six months of follow-up.

次要结局

  • Proportion referred to stress tests.(From enrollement to six months of follow-up.)
  • Proportion referred to Holter monitoring or implantable loop recorders(From enrollement to six months of follow-up.)
  • Proportion with introduction of heart failure (HF) therapy(From enrollement to six months of follow-up.)
  • Proportion referred to cardiac computed tomography (CCT)(From enrollement to six months of follow-up.)
  • Proportion referred to cardiovascular magnetic resonance (CMR)(From enrollement to six months of follow-up.)
  • Proportion with introduction of anti-platelet therapy(From enrollement to six months of follow-up.)
  • Proportion with introduction of anti-coagulant therapy(From enrollement to six months of follow-up.)
  • Proportion referred to percutaneous coronary intervention (PCI)(From enrollement to six months of follow-up.)
  • Proportion referred to cardiac surgery(From enrollement to six months of follow-up.)
  • Proportion referred to electrical cardioversion(From enrollement to six months of follow-up.)
  • Proportion referred to catheter ablation(From enrollement to six months of follow-up.)
  • Proportion referred to pacemaker implantation(From enrollement to six months of follow-up.)
  • Proportion referred to defibrillator implantation(From enrollement to six months of follow-up.)
  • Diagnostic performance of each initial parameter with: sensitivity, specificity, positive predictive value, negative predictive value, and area under the ROC curve.(From enrollement to six months of follow-up.)
  • Cost of care pathways initial and up to 2-5 years(From enrollement to five years of follow-up.)
  • Prognostic value of baseline features to predict medical events annually up to 10 years of follow-up(From enrollement to ten years of follow-up.)
  • Cost-effectiveness of the CESAR care pathway(From enrollement to five years of follow-up.)
  • F1 score of the artificial intelligence model for detecting cardiac involvement(From enrollement to six months of follow-up.)
  • Prognostic value of voice-derived acoustic and speech parameters(At enrollement (D0).)
  • Number of sick leave(From enrollement to five years of follow-up.)
  • Five-year event-free survival(From enrollement to five years of follow-up.)
  • Area under the precision-recall curve (PR-AUC) of the artificial intelligence model for detecting cardiac involvement(From enrollement to six months of follow-up.)
  • Area under the receiver operating characteristic curve (ROC-AUC) of the artificial intelligence model for detecting cardiac involvement(From enrollement to six months of follow-up.)
  • Duration of sick leave(From enrollement to five years of follow-up.)

研究者

申办方类型
Other
责任方
Sponsor

相似试验

Prospective Cohort of Acute Cardiology Referrals in... | 临床试验